The partnership will construct on a decade of impactful collaboration between the University and AstraZeneca and on AstraZeneca’s 30-year heritage in China.
New avenues for change and collaboration
The companions will share their experience and finest apply in constructing profitable ecosystems by means of schooling and coaching, bilateral delegations and boards and expertise exchanges, partaking a spread of establishments throughout each ecosystems together with hospitals, universities, analysis institutes, start-ups and scale-ups.
The University’s innovation arm, Cambridge Enterprise, will ship coaching programmes on analysis commercialisation and spinout creation and will lead on organising reciprocal research visits. Clinicians from the hospitals and medical faculties round Beijing’s BioPark shall be educated in medical management by means of the Cambridge University Medical Education Group (CUMEG), a part of the School of Clinical Medicine.
Patrick Maxwell, Regius Professor of Physic and Head of the School of Clinical Medicine on the University of Cambridge mentioned: “We recognise that China – and Beijing in specific – is an rising centre of innovation in the life sciences. This new partnership creates thrilling alternatives for the University and the broader Cambridge Cluster to additional develop their capabilities by connecting with Beijing’s quickly rising pharma and medtech sector.”
Connecting main innovation hubs
Cambridge’s life sciences ecosystem is the biggest in Europe, anchored by two universities, pioneering analysis institutes, hospitals, and biotech corporations. Its interconnected sectors facilitate speedy collaboration, remodel scientific advances into healthcare innovation, and ship important financial and societal affect.
Beijing stands on the forefront of China’s increasing biopharma and medtech sector, supported by important authorities funding, trendy infrastructure, and a rising pool of medical, scientific, and entrepreneurial expertise.
AstraZeneca’s new R&D centre is situated in the Beijing International Pharmaceutical Innovation Park (BioPark), which follows an identical mannequin of co-location and collaboration because the Cambridge Biomedical Campus – house to AstraZeneca’s strategic R&D facility, The Discovery Centre.
Shaun Grady, Chair of AstraZeneca UK, mentioned: “Collaboration sits at the heart of AstraZeneca’s mission to help transform healthcare and deliver potentially life-changing medicines. With the opening of our new R&D centre in Beijing and The Discovery Centre established in Cambridge, we are proud to help deepen connections between these two leading innovation hubs. This partnership is a fantastic opportunity to share expertise, advance innovation in both regions, and amplify our collective impact – accelerating scientific progress and advancing global public health.”
Dr Jim Glasheen, Chief Executive of Cambridge Enterprise, mentioned: “This partnership with AstraZeneca exemplifies our commitment to building bridges between academia and industry, empowering innovators, and driving global progress in healthcare. By connecting Cambridge’s unique ecosystem with leading partners in Beijing, we are strengthening pathways from lab to clinic, championing improved connectivity and innovation opportunities for the benefit of all.”
A shared dedication to progress for sufferers and society
Fostering deeper connection between the University, AstraZeneca and the 2 innovation ecosystems will empower each areas to be taught from and construct on one another’s experience. United by a shared imaginative and prescient, the partnership will accelerate entry to innovation finest practices and world networks – with the purpose of advancing life sciences in each areas to assist a more healthy future for folks, planet and society globally.
The British Ambassador to the People’s Republic of China, Peter Wilson, mentioned: “This is an excellent example of a leading UK university working in partnership with a leading biopharma company to engage with Beijing’s dynamic innovation ecosystem. This kind of collaboration with China is an important way to accelerate innovation, bolster the UK’s leading life sciences cluster, support growth and help develop new treatments for patients globally.”
Earlier this yr, the University of Cambridge and AstraZeneca marked a decade of collaboration and impact, highlighting achievements in breakthrough science, expertise improvement, and innovation in Cambridge, the UK and past.
.